Nonpharmacologic Treatment of Chronic Graft-versus-Host Disease in Children and Adolescents

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Lawitschka, Anita ^a   Ball, Lynne ^b   Peters, Christina ^c  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Children; Chronic graft versus host disease; Extracorporeal photopheresis; Mesenchymal stromal cells

Indexed keywords

CALCIUM; VITAMIN D;

ABSORPTIOMETRY; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATROPHY; BLEPHARITIS; BONE DENSITY; BONE DISEASE; BRONCHIOLITIS OBLITERANS; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; DIETARY INTAKE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERKERATOSIS; KERATOPATHY; LICHEN PLANUS; LIVER DISEASE; LUNG DISEASE; MESENCHYMAL STROMA CELL; MORBIDITY; MORTALITY; MOUTH DISEASE; MUCOCELE; OBSTRUCTIVE JAUNDICE; PHOTOTHERAPY; PLETHYSMOGRAPHY; POIKILODERMA; RESISTANCE TRAINING; SKIN EXFOLIATION; ULTRAVIOLET B RADIATION; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION; MALE; PHOTOPHERESIS; SALVAGE THERAPY; STROMAL CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855368830     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.001     Document Type: Article

References (45)

1. Fraser C.J., Bhatia S., Ness K., et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006, 108:2867-2873.
2. Zecca M., Prete A., Rondelli R., et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002, 100:1192-1200.
3. Meisel R., Laws H.J., Balzer S., et al. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant 2007, 13:1338-1345.
4. Dietrich T.C.C., Westekemper H., Eberwein P., et al. Diagnosis and treatment of ocular chronic graft-versus-host disease (GVHD): report from the German-Austrian-Swiss Consensus Conference on clinical practice in chronic GVHD. Cornea 2011.
5. Meier J.K., Wolff D., Pavletic S., et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Invest 2011, 15:127-139.
6. Hildebrandt G.C., Fazekas T., Lawitschka A., et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011, 46:1283-1295.
7. Grauer O., Wolff D., Bertz H., et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain 2010, 133:2852-2865.
8. Papadimitriou J.C., Cangro C.B., Lustberg A., et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003, 11:295-302.
9. Browning B., Thormann K., Seshadri R., Duerst R., Kletzel M., Jacobsohn D.A. Weight loss and reduced body mass index: a critical issue in children with multiorgan chronic graft-versus-host disease. Bone Marrow Transplant 2006, 37:527-533.
10. Jacobsohn D.A. Optimal management of chronic graft-versus-host disease in children. Br J Haematol 2010, 150:278-292.
11. Melin-Aldana H., Thormann K., Duerst R., Kletzel M., Jacobsohn D.A. Hepatitic pattern of graft versus host disease in children. Pediatr Blood Cancer 2007, 49:727-730.
12. Hautmann A.H., Elad S., Lawitschka A., et al. Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transpl Int 2011, 24:867-879.
13. Leung W., Ahn H., Rose S.R., et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) 2007, 86:215-224.
14. Wolff D., Gerbitz A., Ayuk F., et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010, 16:1611-1628.
15. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
16. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006, 177:2080-2087.
17. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
18. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006, 108:2114-2120.
19. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
20. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
21. Jung J., Moon N., Ahn J.Y., et al. Mesenchymal stromal cells expanded in human allogenic cord blood serum display higher self-renewal and enhanced osteogenic potential. Stem Cells Dev 2009, 18:559-571.
22. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
23. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
24. Corcione A., Benvenuto F., Ferretti E., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
25. Yanez R., Lamana M.L., Garcia-Castro J., Colmenero I., Ramirez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have invivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006, 24:2582-2591.
26. Zhang J., Li Y., Chen J., et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005, 195:16-26.
27. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
28. Zhou H., Guo M., Bian C., et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010, 16:403-412.
29. Weng J.Y., Du X., Geng S.X., et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45:1732-1740.
30. Barr M.L., Meiser B.M., Eisen H.J., et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 1998, 339:1744-1751.
31. Kuzmina Z., Greinix H.T., Knobler R., et al. Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Blood 2009, 114:744-746.
32. Maeda A., Schwarz A., Kernebeck K., et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005, 174:5968-5976.
33. Greinix H.T., Worel N., Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:1747-1748. author reply 1749.
34. Knobler R., Barr M.L., Couriel D.R., et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol 2009, 61:652-665.
35. Perotti C., Torretta L., Viarengo G., et al. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica 1999, 84:237-241.
36. Messina C., Locatelli F., Lanino E., et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
37. Perotti C., Del Fante C., Tinelli C., et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010, 50:1359-1369.
38. Kanold J., Merlin E., Halle P., et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007 Dec, 47(12):2276-2289.
39. Schooneman F. Extracorporeal photopheresis technical aspects. Transfus Apher Sci 2003, 28:51-61.
40. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006, 91:405-408.
41. Duzovali O., Chan K.W. Intensive extracorporeal photochemotherapy in pediatric patients with chronic graft-versus-host disease (cGVHD). Pediatr Blood Cancer 2007, 48:218-221.
42. Andreu G., Leon A., Heshmati F., et al. Extracorporeal photochemotherapy: evaluation of two techniques and use in connective tissue disorders. Transfus Sci 1994, 15:443-454.
43. Gerber M., Gmeinhart B., Volc-Platzer B., Kalhs P., Greinix H., Knobler R. Complete remission of lichen-planus-like graft-versus-host disease (GVHD) with extracorporeal photochemotherapy (ECP). Bone Marrow Transplant 1997, 19:517-519.
44. Hackstein H., Misterek J., Nockher A., Reiter A., Bein G., Woessmann W. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications. Transfusion 2009, 49:2366-2373.
45. Suchin K.R., Cassin M., Washko R., et al. Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. J Am Acad Dermatol 1999, 41:980-986.